![conference banner](/images/conference-banner.jpeg)
Abstract
Design of cancer-targeting nanotherapeutics relies on a pair of two functionally orthogonal molecules, one serving as a cancer cell-specific targeting ligand, and the other as a therapeutic cytotoxic agent. The present study investigates the validity of an alternative simplified strategy where a dual-acting molecule which bears both targeting and cytotoxic activity is conjugated to the nanoparticle as cancer-targeting nanotherapeutics. Herein, we demonstrate that methotrexate is applicable for this dual-acting strategy due to its reasonable affinity to folic acid receptor (FAR) as a tumor biomarker, and cytotoxic inhibitory activity of cytosolic dihydrofolate reductase. This article describes design of new methotrexate-conjugated poly(amidoamine) (PAMAM) dendrimers, each carrying multiple copies of methotrexate attached through a stable amide linker. We evaluated their dual biological activities by performing surface plasmon resonance spectroscopy, a cell-free enzyme assay and cell-based experiments in FAR-overexpressing cells. This study identifies the combination of an optimal linker framework and multivalency as the two key design elements that contribute to achieving potent dual activity.
Keywords: Folate receptor, methotrexate, dihydrofolate reductase, PAMAM dendrimer, multivalent binding, drug delivery.
Current Pharmaceutical Design
Title:Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic
Volume: 19 Issue: 37
Author(s): Thommey P. Thomas, Melvin Joice, Madhuresh Sumit, Justin E. Silpe, Alina Kotlyar, Sophia Bharathi, Jolanta Kukowska-Latallo, James R. Baker and Seok Ki Choi
Affiliation:
Keywords: Folate receptor, methotrexate, dihydrofolate reductase, PAMAM dendrimer, multivalent binding, drug delivery.
Abstract: Design of cancer-targeting nanotherapeutics relies on a pair of two functionally orthogonal molecules, one serving as a cancer cell-specific targeting ligand, and the other as a therapeutic cytotoxic agent. The present study investigates the validity of an alternative simplified strategy where a dual-acting molecule which bears both targeting and cytotoxic activity is conjugated to the nanoparticle as cancer-targeting nanotherapeutics. Herein, we demonstrate that methotrexate is applicable for this dual-acting strategy due to its reasonable affinity to folic acid receptor (FAR) as a tumor biomarker, and cytotoxic inhibitory activity of cytosolic dihydrofolate reductase. This article describes design of new methotrexate-conjugated poly(amidoamine) (PAMAM) dendrimers, each carrying multiple copies of methotrexate attached through a stable amide linker. We evaluated their dual biological activities by performing surface plasmon resonance spectroscopy, a cell-free enzyme assay and cell-based experiments in FAR-overexpressing cells. This study identifies the combination of an optimal linker framework and multivalency as the two key design elements that contribute to achieving potent dual activity.
Export Options
About this article
Cite this article as:
Thomas P. Thommey, Joice Melvin, Sumit Madhuresh, Silpe E. Justin, Kotlyar Alina, Bharathi Sophia, Kukowska-Latallo Jolanta, Baker R. James and Choi Ki Seok, Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/1381612811319370004
DOI https://dx.doi.org/10.2174/1381612811319370004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Apoptosis: THE Role of Hydrazones
Mini-Reviews in Medicinal Chemistry Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine Antileishmanial Patents Antileishmanial Current Drugs and Relevant Patents
Recent Patents on Anti-Infective Drug Discovery Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Ocular Inflammation and Depression: Ophthalmologists’ Perspective
Current Topics in Medicinal Chemistry Melanogenesis Inhibitors: Strategies for Searching for and Evaluation of Active Compounds
Current Medicinal Chemistry Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer
Drug Design Reviews - Online (Discontinued) Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy
Current Cancer Drug Targets Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia
Current Cancer Drug Targets Oncogenic Properties of HIV-Tat in Colorectal Cancer Cells
Current HIV Research Liposome-Nanogel Structures for Future Pharmaceutical Applications: An Updated Review
Current Pharmaceutical Design